Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Mar;5(1):129-131.
doi: 10.1007/s41669-020-00243-6. Epub 2020 Dec 14.

Hospital Length of Stay for Patients with Severe COVID-19: Implications for Remdesivir's Value

Michaela R Anderson  1 , Peter B Bach #  2 , Matthew R Baldwin #  3
Affiliations

Hospital Length of Stay for Patients with Severe COVID-19: Implications for Remdesivir's Value

Michaela R Anderson et al. Pharmacoecon Open. 2021 Mar.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Dr. Anderson has no conflicts of interest that are directly relevant to the content of this article. Dr. Baldwin served as site co-investigator for Gilead Sciences Remdesivir trials GS-US-540-5774 and GS-US-540-5773 and received no funding. Dr. Bach has received personal fees and non-financial support from the American Society for Health-System Pharmacists, United Rheumatology, Oppenheimer & Co, Kaiser Permanente Institute for Health Policy, the Congressional Budget Office, America’s Health Insurance Plans, and Geisinger; personal fees from WebMD, Defined Health, JMP Securities, Mercer, Foundation Medicine, Grail, Morgan Stanley, NYS Rheumatology Society, Cello Health, Anthem, Magellan Health, EQRx, Meyer Cancer Center of Weill Cornell Medicine, and the National Pharmaceutical Council; personal fees, non-financial support, and other support from Oncology Analytics; and grants from Kaiser Permanente and Arnold Ventures. All listed support was outside the submitted work.

Figures

Fig. 1
Fig. 1
Frequency histogram by age groups for hospital length of stay among patients with severe coronavirus 2019 with hospital length of stay of 1–4 days (n = 586 [36%]), 5–8 days (n = 384 [23%]), and ≥ 9 days (n = 673 [41%])
See this image and copyright information in PMC

Update of

References

    1. O'Day D. An open letter from Daniel O'Day, chairman and CEO, Gilead sciences. Forst City: Business Wirie; 2020.
    1. Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of Covid-19—preliminary report. N Engl J Med. 2020;383(10):992–994. doi: 10.1056/NEJMc2022236. - DOI - PubMed
    1. Pan H, Peto R, Karim QA, et al. Repurposed antiviral drugs for COVID-19—Interim WHO SOLIDARITY trial results. N Eng J Med. 2020 doi: 10.1056/NEJMoa2023184. - DOI - PMC - PubMed
    1. Spinner CD, Gottlieb RL, Criner GJ, et al. Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial. JAMA. 2020;324(11):1048–1057. doi: 10.1001/jama.2020.16349. - DOI - PMC - PubMed
    1. Coronavirus (COVID-19) Update: FDA issues emergency use authorization for potential COVID-19 treatment. 2020. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19.... Accessed 17 Sep 2020.

LinkOut - more resources